Search
Search Results
-
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data
Aims/hypothesisData-driven diabetes subgroups have shown distinct clinical characteristics and disease progression, although there is a lack of...
-
Canagliflozin protects the cardiovascular system through effects on the gut environment in non-diabetic nephrectomized rats
BackgroundThe gut produces toxins that contribute to the cardiovascular complications of chronic kidney disease. Canagliflozin, a sodium glucose...
-
Canagliflozin Pretreatment Attenuates Myocardial Dysfunction and Improves Postcardiac Arrest Outcomes After Cardiac Arrest and Cardiopulmonary Resuscitation in Mice
ObjectiveThe SGLT2 inhibitor, canagliflozin, not only reduces glycemia in patients with type 2 diabetes but also exerts cardioprotective effects in...
-
Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
BackgroundStudies reporting the effects of metabolic surgery, lifestyle intervention, and intensive insulin therapy for the remission of type 2...
-
Protective effect of canagliflozin on post-resuscitation myocardial function in a rat model of cardiac arrest
BackgroundCurrently, most patients with cardiac arrest (CA) show reversible myocardial dysfunction, hemodynamic instability, systemic inflammation...
